An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial.
BACKGROUND AND AIMS: Standard practice to maintain remission in ulcerative colitis (UC) consists of daily mesalazine therapy. However, frequent dosing is associated with poor adherence and increased failure rates. The PODIUM (Pentasa™ Once Daily In UC Maintenance) randomised control trial showed 2...
Үндсэн зохиолчид: | , , , , |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
2009
|